MGMT and glioblastoma: In multivariate analysis, oncological treatment intensity, completion of adjuvant therapy, and MGMT promoter methylation were independent predictors of survival.<h4>Conclusions</h4>This international clinical dataset of adults diagnosed with glioblastoma since the introduction of the WHO CNS 5 criteria supports the use of conventionally fractionated chemoradiation in fit patients < 70, while hypofractionated regimens are appropriate for those ≥ 70.